According to TipRanks.com, Amusa is a top 100 analyst with an average return of 25.6% and a 50.5% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Adverum Biotechnologies, and Axovant Gene Therapies.
RegenXBio has an analyst consensus of Moderate Buy, with a price target consensus of $80.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $55.23 and a one-year low of $20.04. Currently, RegenXBio has an average volume of 523K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.